title: Mechanisms of human immunodeficiency virus type 2 RNA packaging: efficient trans packaging and selection of RNA copackaging partners.
abstract: Human immunodeficiency virus type 2 (HIV-2) has been reported to have a distinct RNA packaging mechanism, referred to as cis packaging, in which Gag proteins package the RNA from which they were translated. We examined the progeny generated from dually infected cell lines that contain two HIV-2 proviruses, one with a wild-type gag/gag-pol and the other with a mutant gag that cannot express functional Gag/Gag-Pol. Viral titers and RNA analyses revealed that mutant viral RNAs can be packaged at efficiencies comparable to that of viral RNA from which wild-type Gag/Gag-Pol is translated. These results do not support the cis-packaging hypothesis but instead indicate that trans packaging is the major mechanism of HIV-2 RNA packaging. To further characterize the mechanisms of HIV-2 RNA packaging, we visualized HIV-2 RNA in individual particles by using fluorescent protein-tagged RNA-binding proteins that specifically recognize stem-loop motifs in the viral genomes, an assay termed single virion analysis. These studies revealed that >90% of the HIV-2 particles contained viral RNAs and that RNAs derived from different viruses were copackaged frequently. Furthermore, the frequencies of heterozygous particles in the viral population could be altered by changing a 6-nucleotide palindromic sequence at the 5'-untranslated region of the HIV-2 genome. This finding indicates that selection of copackaging RNA partners occurs prior to encapsidation and that HIV-2 Gag proteins primarily package one dimeric RNA rather than two monomeric RNAs. Additionally, single virion analyses demonstrated a similar RNA distribution in viral particles regardless of whether both viruses had a functional gag or one of the viruses had a nonfunctional gag, providing further support for the trans-packaging hypothesis. Together, these results revealed mechanisms of HIV-2 RNA packaging that are, contrary to previous studies, in many respects surprisingly similar to those of HIV-1.
authors: HIV Drug Resistance Program, NCI-Frederick, P.O. Box B, Building 535, Room 336, Frederick, MD 21702, USA.
authors: Na
authors: N
authors: Ni
authors: Olga A
authors: OA
authors: Nikolaitchik
authors: Kari A
authors: KA
authors: Dilley
authors: Jianbo
authors: J
authors: Chen
authors: Andrea
authors: A
authors: Galli
authors: William
authors: W
authors: Fu
authors: V V S P
authors: VV
authors: Prasad
authors: Roger G
authors: RG
authors: Ptak
authors: Vinay K
authors: VK
authors: Pathak
authors: Wei-Shau
authors: WS
authors: Hu
references: Virology. 2006 Jan 20;344(2):391-400
references: 16216294
references: Nature. 2004 Sep 30;431(7008):586-90
references: 15457265
references: J Virol. 2005 Oct;79(19):12515-27
references: 16160179
references: Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9564-8
references: 7937806
references: J Virol. 2001 Dec;75(24):12058-69
references: 11711596
references: Hum Gene Ther. 1998 Jun 10;9(9):1371-80
references: 9650621
references: J Virol. 2004 Nov;78(22):12129-39
references: 15507599
references: Retrovirology. 2005 Jan 18;2:3
references: 15656910
references: Proc Natl Acad Sci U S A. 1976 Apr;73(4):1154-8
references: 57617
references: J Virol. 2010 Jul;84(13):6866-75
references: 20410279
references: J Virol. 1998 Feb;72(2):1195-202
references: 9445018
references: J Virol. 1974 Jul;14(1):152-61
references: 4134468
references: J Virol. 2000 Dec;74(23):11413-7
references: 11070043
references: Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13535-40
references: 19628694
references: J Virol. 2009 Jan;83(2):802-10
references: 18971263
references: Curr Biol. 2003 Jan 21;13(2):161-167
references: 12546792
references: J Med Virol. 2006;78 Suppl 1:S7-S12
references: 16622870
references: Proc Natl Acad Sci U S A. 2003 May 27;100(11):6588-92
references: 12743376
references: J Virol. 1999 Oct;73(10):7923-32
references: 10482539
references: RNA. 2007 Aug;13(8):1341-54
references: 17592043
references: Biochemistry. 2003 Mar 11;42(9):2634-42
references: 12614158
references: J Virol. 1997 Aug;71(8):6218-24
references: 9223521
references: J Virol. 1998 Aug;72(8):6527-36
references: 9658096
references: J Virol. 1999 Apr;73(4):3023-31
references: 10074152
references: Nature. 2006 Nov 9;444(7116):164
references: 17093443
references: Biotechniques. 1993 Jul;15(1):120-7
references: 8363827
references: J Biol Chem. 2001 Aug 24;276(34):32345-52
references: 11397802
references: Virology. 2007 Jul 5;363(2):437-46
references: 17336363
references: Nature. 1989 Jun 1;339(6223):389-92
references: 2786147
references: Science. 1996 Apr 12;272(5259):263-7
references: 8602510
references: J Virol. 2006 Oct;80(19):9651-8
references: 16973569
references: J Virol. 2000 Dec;74(24):11531-7
references: 11090150
references: J Virol. 2002 Apr;76(7):3089-94
references: 11884533
references: J Virol. 2007 Apr;81(7):3285-92
references: 17229705
references: J Mol Biol. 2004 Mar 19;337(2):427-42
references: 15003457
references: J Virol. 2006 May;80(10):4691-7
references: 16641262
references: Nature. 1992 Aug 6;358(6386):495-9
references: 1641038
references: Retrovirology. 2007 Dec 13;4:90
references: 18078509
references: AIDS Rev. 2009 Apr-Jun;11(2):91-102
references: 19529749
references: Nat Rev Microbiol. 2004 Jun;2(6):461-72
references: 15152202
references: J Gen Virol. 2006 Aug;87(Pt 8):2279-2289
references: 16847124
references: Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19248-53
references: 20974908
references: Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9002-7
references: 15956186
references: J Virol. 2007 Apr;81(8):4002-11
references: 17267488
references: Nature. 1999 Feb 4;397(6718):436-41
references: 9989410
references: J Virol. 1998 May;72(5):3991-8
references: 9557686
references: J Mol Biol. 2002 Jun 7;319(3):637-48
references: 12054860
references: J Virol. 2005 Feb;79(3):1666-77
references: 15650192
references: J Virol. 1997 Aug;71(8):6028-36
references: 9223494